Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer (FIRSTLUNG)
Sponsor: Delfi Diagnostics Inc.
A NA clinical study on Lung Cancer, this trial is completed. The trial is conducted by Delfi Diagnostics Inc. and has accumulated 9 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed NA
Status: Recruiting → Completed
-
Aug 2025 — Dec 2025 [monthly]
Recruiting NA
-
Nov 2024 — Aug 2025 [monthly]
Recruiting NA
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting NA
-
Feb 2024 — Apr 2024 [monthly]
Recruiting NA
-
Jan 2024 — Feb 2024 [monthly]
Recruiting NA
-
Dec 2023 — Jan 2024 [monthly]
Recruiting NA
First recorded
Oct 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Delfi Diagnostics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .